JPMorgan Chase & Co. Acquires 1,520 Shares of Immunome, Inc. (NASDAQ:IMNM)

JPMorgan Chase & Co. grew its holdings in Immunome, Inc. (NASDAQ:IMNM) by 6.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,565 shares of the company’s stock after purchasing an additional 1,520 shares during the quarter. JPMorgan Chase & Co.’s holdings in Immunome were worth $359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Intech Investment Management LLC bought a new stake in shares of Immunome during the third quarter valued at approximately $219,000. AQR Capital Management LLC boosted its holdings in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares during the last quarter. XTX Topco Ltd purchased a new position in Immunome in the third quarter valued at approximately $363,000. MetLife Investment Management LLC grew its stake in shares of Immunome by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock worth $442,000 after acquiring an additional 17,053 shares during the period. Finally, Cerity Partners LLC raised its position in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after purchasing an additional 5,043 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Up 1.2 %

Shares of Immunome stock opened at $9.35 on Thursday. The business has a 50 day moving average of $11.32 and a 200 day moving average of $12.77. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96. The company has a market cap of $583.63 million, a PE ratio of -1.15 and a beta of 1.90.

Wall Street Analysts Forecast Growth

IMNM has been the subject of several analyst reports. Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th. Finally, Piper Sandler cut their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has an average rating of “Buy” and a consensus price target of $28.60.

Insider Activity at Immunome

In related news, insider Robert Lechleider purchased 15,805 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were purchased at an average cost of $9.48 per share, with a total value of $149,831.40. Following the transaction, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The shares were bought at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 102,862 shares of company stock worth $978,045 over the last 90 days. 8.60% of the stock is owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.